Vivos Therapeutics reports Nasdaq compliance confirmation

Vivos Therapeutics (VVOS) received a letter from Nasdaq confirming compliance with the stockholders' equity standard of at least $2.5 million. The company announced this on Wednesday.

Original reporting
Published Oct 21, 2026, 11:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VVOS
Bullish
high confidence
Mentioned
$VVOS
Relevance
5/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VVOSBullishLow
01

Why it matters

The confirmation removes a regulatory risk, which may stabilize or slightly lift the share price.

02

Market read

A compliance confirmation that eliminates a delisting risk, offering modest positive sentiment for VVOS.

03

What to watch

Potential future capital raises could be impacted if equity levels fall below the threshold again.

Relevance 5/10Novelty 5/10Timing: today

Background

Nasdaq requires listed companies to maintain at least $2.5 million in stockholders' equity. Non‑compliance can trigger delisting procedures.

Company-level read

Ticker impact

$VVOSBullishHigh confidence
Context

Vivos Therapeutics disclosed receipt of a Nasdaq compliance letter confirming it meets the $2.5M stockholders' equity requirement.

Expected impact

likely modest upside as market prices in reduced regulatory risk

Evidence & confidence

No immediate financial impact, but removal of a downside catalyst can buoy sentiment.

Market effects

Minimal; compliance news is specific to Vivos Therapeutics and does not affect the broader biotech sector.

None; the news is company‑specific.

Low; no broader market impact.

Counterpoint

Investors may view the compliance news as a routine filing with limited upside potential.

Key entities

  • Vivos Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker VVOS.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$SPGIMed

S&P Global prices $2 billion senior notes offering

S&P Global (SPGI) priced a $2 billion senior notes offering in three tranches, with yields ranging from 5.635% to 6.001%. The notes are due 2031, 2034, and 2036, and proceeds will be used for general corporate purposes. The offering is expected to close around November 18, 2026, and is managed by several major financial institutions. The notes will be unsecured obligations of the company, guaranteed by a subsidiary.